Pharmacogenomics in treatment of depression and psychosis: an update

被引:30
|
作者
Jukic, Marin [1 ,2 ]
Milosavljevi, Filip [1 ,2 ]
Molden, Espen [3 ,4 ]
Ingelman-Sundberg, Magnus [1 ]
机构
[1] Karolinska Inst, Dept Physiol & Pharmacol, Pharmacogenet Sect, Stockholm, Sweden
[2] Univ Belgrade, Fac Pharm, Dept Physiol, Belgrade, Serbia
[3] Diakonhjemmet Hosp, Ctr Psychopharmacol, Oslo, Norway
[4] Univ Oslo, Dept Pharm, Sect Pharmacol & Pharmaceut Biosci, Oslo, Norway
基金
瑞典研究理事会; 欧洲研究理事会;
关键词
CONSENSUS GUIDELINES; IMPLEMENTATION CONSORTIUM; CONTROLLED-TRIAL; DISORDER; CYP2D6; NEUROPSYCHOPHARMACOLOGY; METAANALYSIS; REMISSION; EFFICACY; IMPACT;
D O I
10.1016/j.tips.2022.09.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Genetic factors can, to a certain extent, successfully predict the therapeutic effects, metabolism, and adverse reactions of drugs. This research field, pharmacogenomics, is well developed in oncology and is currently expanding in psychiatry. Here, we summarize the latest development in pharmacogenomic psychiatry, where results of several recent large studies indicate a true benefit and cost-effectiveness of pre-emptive genotyping for more successful psychotherapy. However, it is apparent that we still lack knowledge of many additional heritable genetic factors of importance for explanation of the interindividual differences in response to psychiatric drugs. Thus, more effort to further develop pharmacogenomic psychiatry should be invested to achieve a broader clinical implementation.
引用
收藏
页码:1055 / 1069
页数:15
相关论文
共 50 条
  • [1] Pharmacogenomics in the treatment of lung cancer: an update
    Morales-Espinosa, Daniela
    Garcia-Roman, Silvia
    Karachaliou, Niki
    Rosell, Rafael
    PHARMACOGENOMICS, 2015, 16 (15) : 1751 - 1760
  • [2] Foreword: Update on the Treatment of Depression and Pharmacogenomics Testing in Children and Adolescents: Dr. Strawn and Colleagues
    Pascoe, John M.
    CURRENT PROBLEMS IN PEDIATRIC AND ADOLESCENT HEALTH CARE, 2018, 48 (02) : 29 - 30
  • [3] The pharmacogenomics of depression
    Licinio J.
    The Pharmacogenomics Journal, 2001, 1 (3) : 175 - 177
  • [4] Drug interactions and pharmacogenomics in the treatment of breast cancer and depression
    Henry, N. Lynn
    Stearns, Vered
    Flockhart, David A.
    Hayes, Daniel F.
    Riba, Michelle
    AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (10): : 1251 - 1255
  • [5] Novel treatment options in depression and psychosis
    Ceskova, Eva
    Silhan, Petr
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 741 - 747
  • [6] An update on the treatment of bipolar depression
    Azorin, Jean-Michel
    Kaladjian, Arthur
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (02) : 161 - 172
  • [7] EXERCISE AS A TREATMENT FOR DEPRESSION - AN UPDATE
    SIMONS, AD
    MCGOWAN, CR
    EPSTEIN, LH
    KUPFER, DJ
    ROBERTSON, RJ
    CLINICAL PSYCHOLOGY REVIEW, 1985, 5 (06) : 553 - 568
  • [8] Treatment of bipolar depression: An update
    Fountoulakis, Konstantinos N.
    Grunze, Heinz
    Panagiotidis, Panagiotis
    Kaprinis, George
    JOURNAL OF AFFECTIVE DISORDERS, 2008, 109 (1-2) : 21 - 34
  • [9] Update on the treatment for refractary depression
    Hernandez Fleta, J. L.
    Terres Ruiz, M. E.
    Sanchez-Arana Moreno, T.
    Salesansky Davidovsky, A.
    Dominguez Santana, A.
    Zerek Benitez, E.
    EUROPEAN PSYCHIATRY, 2007, 22 : S231 - S232
  • [10] DEPRESSION DUE TO TREATMENT OF SCHIZOPHRENIC PSYCHOSIS
    MULLER, P
    FORTSCHRITTE DER MEDIZIN, 1978, 96 (30) : 1518 - 1520